Catalyst Biosciences CMO Howard Levy retires, transitions to consultant through Sept 2022

GYRE THERAPEUTICS, INC.

Howard Levy retired as CMO effective Aug 15, 2021; consulting role until Sept 30, 2022.
Consulting at customary hourly rate; vested options exercisable 90 days after termination.
Levy to provide consulting on hemophilia programs; non-compete in Factor VIIa/IX and complement areas.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Howard Levy

Chief Medical Officer

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2021-08-15
Filed: August 16, 2021, 7:59 PM ET

Howard Levy, M.B.B.Ch, Ph.D., M.M.M. its Chief Medical Officer plans to retire effective August 15, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Levy retired as Chief Medical Officer at GYRE THERAPEUTICS, INC..

Action: retired
Role: Chief Medical Officer

Exact text from the filing

Howard Levy, M.B.B.Ch, Ph.D., M.M.M. its Chief Medical Officer plans to retire effective August 15, 2021

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-247691

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.